Company Shares of Immunomedics (NASDAQ:IMMU) Rally 5.08%

Immunomedics (NASDAQ:IMMU) has been under a strong bear grip, hence the stock is down -19.98% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.76% in the past 1 week. The stock has risen by 5.08% in the past week indicating that the buyers are active at lower levels, but the stock is down -18.69% in the past 4 weeks.

The company shares have dropped -41.65% from its 1 Year high price. On Jun 2, 2016, the shares registered one year high at $5.44 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $3.25 and the 200 Day Moving Average price is recorded at $2.81.

The stock has recorded a 20-day Moving Average of 2.63% and the 50-Day Moving Average is 27.93%.


Immunomedics (NASDAQ:IMMU): stock turned positive on Friday. Though the stock opened at $2.35, the bulls momentum made the stock top out at $2.5 level for the day. The stock recorded a low of $2.31 and closed the trading day at $2.48, in the green by 4.64%. The total traded volume for the day was 1,082,575. The stock had closed at $2.37 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Goldenberg David M, director officer (CSO & Chairman of the BOD) of Immunomedics Inc, had unloaded 371,990 shares at an average price of $3.04 in a transaction dated on June 10, 2016. The total value of the transaction was worth $1,130,850.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *